Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

• Status: Recruiting
• Trial end date: 2027-12-28

Summary

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

• Phase: Phase 3

Details

• Lead Sponsor: AstraZeneca
• Collaborators: European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation, Inc. (GOG Foundation); Myriad Genetic Laboratories, Inc.
• Treatments: Antibodies, Monoclonal; Bevacizumab; Carboplatin; Durvalumab; Olaparib; Paclitaxel